New Research from Foundation Medicine and Roche Demonstrates Improved Outcomes Following Treatment Based on Comprehensive Genomic Profiling in Patients with Cancer of Unknown Primary Origin (CUP)Business Wire • 10/20/23
Roche (RHHBY) Nine Months' Sales Fall on Lower COVID-19 Test SaleZacks Investment Research • 10/19/23
Drug Giant Roche Skids As Covid Products Decline Weighs On Sales, GuidanceInvestors Business Daily • 10/19/23
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports good sales growth despite decline in demand for COVID-19 productsGlobeNewsWire • 10/19/23
Together for CHANGE Genomics and Equity Initiative Launched by a Coalition of Meharry Medical College, Regeneron Genetics Center, AstraZeneca, Novo Nordisk, and Roche to Improve Health Outcomes for People of African AncestryBusiness Wire • 10/18/23
Roche IL-6 is the first immunoassay approved to aid sepsis diagnosis in newbornsGlobeNewsWire • 10/18/23
Roche's Alecensa reduces the risk of disease recurrence or death by an unprecedented 76% in people with ALK-positive early-stage non-small cell lung cancerGlobeNewsWire • 10/18/23
Genentech's Alecensa Reduces the Risk of Disease Recurrence or Death by an Unprecedented 76% in People With ALK-Positive Early-Stage Non-Small Cell Lung CancerBusiness Wire • 10/18/23
Late-Breaking Data for Genentech's BTK Inhibitor Fenebrutinib Show Brain Penetration and Significant Reduction in Lesions in Patients With Relapsing Multiple SclerosisBusiness Wire • 10/13/23
Late-breaking data for Roche's BTK inhibitor fenebrutinib show brain penetration and significant reduction in lesions in patients with relapsing multiple sclerosisGlobeNewsWire • 10/13/23
New data for Roche's OCREVUS show that after 10 years of treatment 77% of people with relapsing multiple sclerosis were free from disability progression and 92% continue to walk unaidedGlobeNewsWire • 10/12/23
New Data for Genentech's Ocrevus Show That After 10 Years of Treatment 77% of People With Relapsing Multiple Sclerosis Were Free From Disability Progression and 92% Continue to Walk UnaidedBusiness Wire • 10/12/23
Roche's OCREVUS twice-yearly, 10-minute subcutaneous injection was non-inferior to intravenous infusion and provided near-complete suppression of brain lesionsGlobeNewsWire • 10/11/23
Genentech's Ocrevus Twice-Yearly, 10-Minute Subcutaneous Injection Was Non-Inferior to Intravenous Infusion and Provided Near-Complete Suppression of Brain LesionsBusiness Wire • 10/11/23
Roche's Vabysmo maintained vision improvements with extended treatment intervals up to four months for people with retinal vein occlusion (RVO) in phase III studiesGlobeNewsWire • 10/10/23
Genentech's Vabysmo Maintained Vision Improvements With Extended Treatment Intervals Up to Four Months for People With Retinal Vein Occlusion (RVO) in Phase III TrialsBusiness Wire • 10/10/23
Majority of newborn babies with spinal muscular atrophy (SMA) treated with Roche's Evrysdi able to sit independently after 1 year of treatmentGlobeNewsWire • 10/04/23
Majority of Newborn Babies With Spinal Muscular Atrophy (SMA) Treated With Genentech's Evrysdi Able to Sit Independently After 1 Year of TreatmentBusiness Wire • 10/04/23
Roche to present new key clinical and real-world data at ECTRIMS-ACTRIMS 2023 showcasing strength of long-term outcomes in MS and NMOSDGlobeNewsWire • 10/02/23
